Royalty Pharma acquires all remaining royalty interests in Roche's Evrysdi for $240 million
On December 29th local time, biopharmaceutical company Royalty Pharma announced that it has acquired all remaining royalty interests in Roche's Evrysdi drug held by PTC Therapeutics. The transaction includes a $240 million upfront payment and up to $60 million in sales milestone payments. Royalty Pharma stated that the increased royalty rate will apply starting in the first quarter of 2026 based on Evrysdi's sales in the fourth quarter of 2025. In 2024, Evrysdi's sales are expected to be approximately 1.6 billion Swiss francs (equivalent to $1.9 billion), representing an 18% year-on-year growth at constant exchange rates. (Jiemian)
Source: 36Kr The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments